NDT Pharmaceuticals Inc. (NDTP)
USD 0.07
(-58.27%)
USD 0.07
(-58.27%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.16 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 1240.00 USD | -35.72% |
| 2016 | 1929.00 USD | -97.79% |
| 2015 | 87.33 Thousand USD | -66.5% |
| 2014 | 260.67 Thousand USD | 0.0% |
| 2010 | 253.75 Thousand USD | 0.0% |
| 2007 | 61.43 Thousand USD | 63.68% |
| 2006 | 37.53 Thousand USD | 550.11% |
| 2005 | 5773.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1520.00 USD | -44.16% |
| 2024 Q3 | 2200.00 USD | -78.36% |
| 2024 Q2 | 10.16 Thousand USD | 568.82% |
| 2023 Q4 | 2722.00 USD | 32.33% |
| 2023 FY | 25.16 Thousand USD | 0.0% |
| 2023 Q1 | 11.26 Thousand USD | 0.0% |
| 2023 Q2 | 9126.00 USD | -18.98% |
| 2023 Q3 | 2057.00 USD | -77.46% |
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 1240.00 USD | -35.72% |
| 2016 FY | 1929.00 USD | -97.79% |
| 2015 FY | 87.33 Thousand USD | -66.5% |
| 2014 FY | 260.67 Thousand USD | 0.0% |
| 2011 Q1 | 22.54 Thousand USD | 10.68% |
| 2011 Q2 | 12.23 Thousand USD | -45.72% |
| 2010 Q1 | 12.95 Thousand USD | 0.0% |
| 2010 FY | 253.75 Thousand USD | 0.0% |
| 2010 Q4 | 20.37 Thousand USD | 61.45% |
| 2010 Q3 | 12.61 Thousand USD | -93.93% |
| 2010 Q2 | 207.81 Thousand USD | 1504.6% |
| 2008 Q1 | 20.74 Thousand USD | -2.78% |
| 2008 Q2 | 33.24 Thousand USD | 60.25% |
| 2007 Q3 | 18.14 Thousand USD | 53.75% |
| 2007 FY | 61.43 Thousand USD | 63.68% |
| 2007 Q4 | 21.33 Thousand USD | 17.62% |
| 2007 Q1 | 10.15 Thousand USD | -31.48% |
| 2007 Q2 | 11.8 Thousand USD | 16.23% |
| 2006 Q4 | 14.81 Thousand USD | 91.97% |
| 2006 Q2 | 3761.00 USD | -66.44% |
| 2006 Q1 | 11.2 Thousand USD | 0.0% |
| 2006 Q3 | 7718.00 USD | 105.21% |
| 2006 FY | 37.53 Thousand USD | 550.11% |
| 2005 FY | 5773.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 98.115% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.501% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.915% |
| Nascent Biotech, Inc. | 2.22 Million USD | 98.871% |
| Rebus Holdings, Inc. | 664 Thousand USD | 96.209% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.932% |
| Qrons Inc. | 643.67 Thousand USD | 96.09% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 93.539% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.956% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 93.942% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.814% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.971% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.488% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 90.383% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.971% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.137% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 98.324% |
| Mesoblast Limited | 5.9 Million USD | 99.574% |
| Marizyme, Inc. | 19.23 Million USD | 99.869% |
| Genus plc | 147.7 Million USD | 99.983% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.713% |
| Pharming Group N.V. | 225.49 Million USD | 99.989% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 98.771% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 98.124% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.698% |
| ContraFect Corporation | 56.88 Million USD | 99.956% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.429% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 98.298% |
| IMV Inc. | 37.7 Million USD | 99.933% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.098% |
| MultiCell Technologies, Inc. | 567.42 USD | -4335.691% |
| ONE Bio Corp. | 6.44 Million USD | 99.609% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.328% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.971% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 95.269% |
| Q BioMed Inc. | 3.43 Million USD | 99.268% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.898% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 99.042% |
| Biomind Labs Inc. | 994.18 Thousand USD | 97.468% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.975% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 98.57% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.625% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 98.65% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 200.676% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.843% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 98.628% |
| GB Sciences, Inc. | 1.42 Million USD | 98.228% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.741% |
| HST Global, Inc. | 140.9 Thousand USD | 82.138% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 97.763% |
| Halberd Corporation | 74.84 Thousand USD | 66.37% |
| Enzolytics Inc. | 2.17 Million USD | 98.845% |
| Agentix Corp. | 1.37 Million USD | 98.165% |
| Resverlogix Corp. | 12.71 Million USD | 99.802% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.311% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 97.589% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 98.953% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 98.406% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.261% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.656% |
| Zenith Capital Corp. | 8.94 Million USD | 99.719% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.997% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -44.475% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 98.975% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 85.325% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 98.69% |
| Kadimastem Ltd | 2.41 Million USD | 98.956% |
| Helix BioMedix, Inc. | 1.97 Million USD | 98.724% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.768% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.89% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 86.132% |
| LadRx Corporation | 3.81 Million USD | 99.34% |
| Cell Source, Inc. | 4.32 Million USD | 99.418% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.275% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.275% |
| NovAccess Global Inc. | 2.46 Million USD | 98.98% |
| Affymax, Inc. | 39.38 Million USD | 99.936% |
| Itoco Inc. | 919.14 Thousand USD | 97.262% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.406% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 97.751% |
| Mobile Lads Corp. | 554.54 Thousand USD | 95.461% |
| CytoDyn Inc. | 18.05 Million USD | 99.861% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 88.564% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 98.227% |
| SYBLEU INC | 160.87 Thousand USD | 84.355% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 98.614% |
| International Stem Cell Corporation | 5.27 Million USD | 99.523% |
| Bioxytran, Inc. | 3.82 Million USD | 99.341% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 52.188% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -23.723% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.931% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 98.444% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 96.58% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.191% |
| Neutra Corp. | 243.82 Thousand USD | 89.677% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.856% |
| PureTech Health plc | 144.59 Million USD | 99.983% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.877% |
| IXICO plc | 4.7 Million USD | 99.465% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.714% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.979% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.974% |